Audited Results - Year ended March 31, 2026

Pfizer Limited

The Capital, 1802/1901,

Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051.

Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

May 12, 2026

The Corporate Relationship Dept. BSE Limited

1stFloor, P.J.Towers Dalal Street, Fort Mumbai - 400 001

Scrip Code: 500680

The Manager, Listing Dept.

The National Stock Exchange of India Ltd. Exchange Plaza, 5thFloor, Plot No. C/1,

G Block Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051

Scrip Symbol: PFIZER

Dear Sirs / Madam,

Sub: Outcome of Board Meeting held on May 12, 2026.

Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its Meeting held today, i.e., May 12, 2026, that commenced at 1.30 p.m. and concluded at

6.30 p.m., inter alia, approved the following businesses:

Audited Financial Results:

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith (i) Audited Financial Results for the financial year ended March 31, 2026, (ii) Statement of Assets and Liabilities as on March 31, 2026,

1. Statement of Audited Cash Flows for the year ended March 31, 2026,

2. Declaration with respect to the Audit Report with unmodified opinion and

3. Auditor's Report by the Statutory Auditors, M/s. B S R & Co., LLP , in respect of the said Audited Financial Results.

Dividend and Record Date:

The Board of Directors at its meeting held on May 12, 2026, have recommended a final dividend of Rs. 75/- per equity share of Rs. 10/- each (750%) for the financial year ended March 31, 2026.

The said dividend, if declared at the ensuing Annual General Meeting of the Company, shall be paid on or after August 4, 2026, to those shareholders whose name appear in the Register of Members of the Company as on the Record date i.e., Friday, July 17, 2026.

Convening of the 75thAnnual General Meeting of the Company on Tuesday, July 28, 2026, through Video-Conferencing ("VC") / Other Audio-Visual Means ("OAVM") in accordance with the relevant Circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India.

CIN: L24231MH1950PLC008311

Email ID: contactus.india@pfizer.com

Website: https://www.pfizerltd.co.in

The Board of Directors upon recommendation of the Audit Committee, at its meeting held on May 12, 2026, appointed M/s. Kishore Bhatia & Associates (Firm Registration No. 000294) as the Cost Auditors of the Company for the financial year ending March 31, 2027. The remuneration payable to M/s. Kishore Bhatia & Associates shall be placed before the shareholders for ratification at the ensuing Annual General Meeting.

Details pursuant to SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed as Annexure A.

Non-Applicability of Annual Disclosure to be made by an entity identified as a Large Corporate:

We hereby confirm that, (i) the Company has not issued any debt securities and non-convertible redeemable preference shares, (ii) the Company does not have any outstanding long-term borrowings exceeding Rs. 1,000 Crores and (iii) the Company has not obtained any credit ratings relating to borrowings.

Accordingly, the Company does not fall under the category of Large Corporate as on March 31, 2026, in terms of SEBI circular No. SEBI/HO/DDHS/DDHS RACPOD1/P/CIR/ 2023/172 dated October 19, 2023, and amendments thereof.

We request you to please take the above on record. Thanking you,

Yours truly,

Prajeet

For Pfizer Limited

Digitally signed by Prajeet Nair

Nair

Date: 2026.05.12

19:20:03 +05'30'

Prajeet Nair

Director - Corporate Services & Company Secretary Encl.: A/a

Annexure A

B S R & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing Nesco IT Park 4, Nesco Center

Western Express Highway

Goregaon (East), Mumbai - 400 063, India Telephone: +91 (22) 6257 1000

Fax: +91 (22) 6257 1010

To the Board of Directors of Pfizer Limited

Report on the audit of the Annual Financial Results

We have audited the accompanying annual financial results of Pfizer Limited (hereinafter referred to as the "Company") for the year ended 31 March 2026, attached herewith. being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid annual financial results:

1. are presented In accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

2. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the year ended 31 Mamh 2026.

We conducted our audit in accordance with the Standards on Auditing ("SAs*) specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responslbililies for I/ie Audit of the Annual Financial Results section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical raquirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion on the annual financial results.

These annual financial results have been prepared on the basis of the annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these annual financial results that give a tnie and fair view of the net profit/ loss and other comprehensive Income and other financial information in accordance with the recognition and measurement principles laid down In Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 32 of the Listing Regulations. This responsibility also includes maintenance of adequate aocounting records in accordance with the provisions of the Act for safeguarding of the aasets of the Company and for preventing and detecting frauds and other irragularities; selection and application of appropriate accounting policies: making judgments and esGmates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls. that were operating effectively for ensuring accuracy and completeness of the aoCounting records, relevant to the preparation and presentation of the annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the annual financial results, the Management and the Board of Directors are responsible for

ReglMered OGce-

Page 1 of 3

B S R & Co. LLP

Pfizer Limited

assessing the Company's ability to continue as a going c‹mcern, disclosing, as apphcable, matters related to going concern and using the going concern basis of accounting unless the Board of Oirectors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Our objectives are to obtain reasonable assurance about whether the annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that indudes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expecmd to influence the economic decisions of users taken on the basis of these annual financial results.

As part of an audit in accordance with 5As, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the annual financial results, whether due to fraud or error, design and perform audit procadures responsive to those risks, and obtain audit evidence that is sufficien! and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions. misrepresentations, or the override of internal control.

• Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

• Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures In the annual financial results made by the Management and Board of Directors.

• Conclude on the appropriateness of the Management's and Board of Directors' use of the e••s concern basis of accounting and, based on the audit evidence obtained, whether a materiai uncerlainty exists related to events or conditions that may cast significant doubt on the

appropriateness of this assumption. If we conclude that a material uncertainty exists, wa are required to draw attention in our auditor's report to the related disclosures in the annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may causa tha Company to cease to continue as a going concern.

Evaluate the overall presentation, structure and content of the annual financial results, including the disclosures, and whether the annual financial results represent the underlying transactions and events ina manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

The annual financial results include the results for the quarter ended 31 March 2026 being fhe balancing

figure between the audited figures in respect of the full financial year and the published unaudited year to

Page 2 of 3

B S R & Co. LLP

In ne pen ‹lent A rid ito r's Re po rt ( Co r›Eli ‹/ecYJ

Pfizc r L ini ited

date figures up to the third quarter of the current financial year whtch were subject to limited review by us.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No..101248W/W-100022

Mumbai

12 May 2026

Sreeja Marar

Partner Membership No.: 111410 UDiN.2611141oceauRF2484

Page 3 of 3

Pfizer Limited

The Capital. 1802/1901,

Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East). Mumbai 400 051.

Tel : +9f 22 66g3 2000 Fax : +91 22 2654 0274

Sutement of Finandal ResulD for the Quarter and Yaer anded 31 March 2026

zer

(PIncraze cacapt eamlngs pershare

# Earnings per share.- Basic and Diluted before Exceptional Items

°Not annualized

42.?l

40.42

41.01

165.88

136.46

"Purchase of property, plant and equipment represents additions to property, plant and equipment adjusted fOr movement of capica work n progress,capitaI advances and capital creditors during the perlod.

"* Amount below 9 one lakh

Statement of Assets and Liabilities as at 31 March 2026

(7 in crore)

' Amount be)ow R one lakh

1. The above financial results were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on May 12, 2026.

2. The financial results of the Company have been prepared in accordance with Indian Accounting Standards ('Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time).

3. The financial results for the year ended March 31, 2026 have been audited by the statutory auditors of the Company. The audit opinion does not contain any modifications. The audit report will be filed with the Stock Exchanges and will also be available on the Company's website - https://www.pfizerltd.co.in

4. Figures for the quarter ended March 31, 2026 and March 31, 2025 represent the difference between the audited figures in respect of the full financial year and published unaudited figures of nine months ended December 31, 2025 and December 31, 2024 respectively which were subject to a limited review by the statutory auditors.

5. Exceptional Items:

   1. Exceptional items of l:(49.16 crore for the year ended March 31, 2026 includes:

      1. The charge of l:(41.73 crore for the year (nine months ended December 31, 2025 l:(39.58 crore) towards personnel separation cost of field force and marketing teams as a result of an exclusive Supply and Marketing Agreement with Cipla Limited for marketing and distribution of four brands of the Company, viz., Corex Dx, Corex LS, Dolonex, and Neksium and also includes personnel separation cost for other support functions.

      2. Effective 21 November 2025, the Government of India hadconsolidated several existing labour laws into a unified framework consisting of four Labour Codes, collectively known as the 'New Labour Codes'. The Company has carried out an assessment based on the best available information and legal opinion, which has resulted in increase in the provision for employee benefits by l:(7.43 crore for the year (nine months ended December 31, 2025 l:(18.62 crore). The Company continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards.

   2. Exceptional Items for the year ended March 31, 2025 relates to Net gain of U72.81 crore (net of carrying value of �31.75 crore and cost to sell - Premium and other charges �9.84 crore, net of recovery) on account of assignment of Lease of MIDC Land and Sale of Building constructed on such land.

6. The Company has only one segment which is 'Pharmaceuticals'. Therefore, disclosure relating to segments is not applicable and accordingly not made.

1. The Board of Directors have recommended a final dividend of X75 per equity share of CIO each (750%) for the financial year ended March 31, 2026. The proposed dividend amounting to T343.11 crore is subject to the approval of the shareholders in the annual general meeting.

2. The Company does not have any subsidiary company or associate company or joint venture company as at March 31, 2026.

For Pfizer Limited

M v 12, 2026

Meenakshi Nevatia Managing Director

The Capital, 1802/1901,

Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051.

Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

May 12, 2026

P$$xer

The Corporate Relationship Dept. BSE Limited

1" Floor, P.J.Towers Dalal Street, Fort Mumbai -400 001

Scrip Code: 500680

Dear Sirs / Madam,

The Manager, Listing Dept.

The National Stock Exchange of India Ltd. Exchange Plaza, S'h Floor, Plot No. C/1,

G Block Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051

Scrip Sv bol: PFIZER

Subject: Declaration with respect to Audit Reeort with unmodified opinion on the Audited Financial Results for the financial vear ended March 31, 2026.

We hereby declare that the Statutory Auditors have not expressed any modified opinion(s) in their Audit Repon with respect to the Audited Financial Results for the financial year ended March 31, 2026, which have been approved by the Board of Directors of the Company at their meeting held today, i.e., May 12, 2026.

The above declaration is made in pursuant to Regulation 33 (3) (d) of the Securities and Exchange Board of India (Listed Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you, Yours truly,

For Pfizer Limited

Managing Director

Email ID:

Website: